13/10/2015 17:43:13 Cookie Policy Free Membership Login

Ideagen Share Price - IDEA

Share Name Share Symbol Market Type Share ISIN Share Description
Ideagen LSE:IDEA London Ordinary Share GB00B0CM0C50 ORD 1P
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00 +0.00% 46.50 46.00 47.00 46.50 46.50 46.50 67,102 07:41:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) RN NRN
Software & Computer Services 14.4 0.6 0.4 132.9 82.69

Ideagen News, Charts, Forums & Trades

More Ideagen News
Ideagen Takeover Rumours

Ideagen Share Charts

1 Year Ideagen Chart

1 Year Ideagen Chart

1 Month Ideagen Chart

1 Month Ideagen Chart

Intraday Ideagen Chart

Intraday Ideagen Chart

Ideagen Discussions and Chat

Ideagen Top Chat Posts

rivaldo: Shares Mag are positive this week about IDEA: "Ideagen eyes record breakers Red tape software firm anticipates new business scale-up COMPLIANCE AND RISK management software supplier Ideagen (IDEA:AIM) hopes to beat its biggest contract success to date with the help of public cloud platform, Amazon Web Services (AWS). Ideagen’s software-as-a-service (SaaS) AWS-based risk and compliance toolset is called Enlighten and analysts believe it will be fundamental to the company scaling up its new business victories, and should drive the 47p share price higher. The UK Government remains committed to its ‘paperless NHS’ initiative, launched in 2013 under the previous coalition leadership, but largely driven by current conservative Secretary of State for Health, Jeremy Hunt. The aim is for a completely digitised patient records system by 2018, an objective that provides huge new business opportunities for Peak District-based Ideagen, as will expansion in other verticals, say analysts. ‘With the sales and marketing teams integrated into a single entity, management anticipates opportunities to cross-sell the group’s capabilities into existing clients and win new clients in the aviation, defence, transport and healthcare markets,’ spells out Michael Larner, an analyst at IT consultancy website TechMarketViews. Ideagen’s biggest single win to date is the £1 million deal with the Doncaster and Bassetlaw NHS Trust secured on 2 October 2014. SHARES SAYS: Rising red tape remains a big growth engine for the small cap."
rivaldo: Dilip/GHF, it's also worth factoring in to calculations that IDEA have a fast-growing cash pile - £5.3m at 30/4/15 - to incorporate into any share price targets, not least because I'm sure IDEA are on the lookout for more earnings-enhancing acquisitions. Nice plug from Penny Share Pro's e-mailed newsletter this morning: "Ideagen lands new contracts Ideagen, a leading supplier of information management software, recently announced it’s won two new deals with a combined value of £1 million. The contracts, one with a top 4 global accounting firm and the other with a leading global petrochemicals group, are for Ideagen's Governance Risk and Compliance products. It’s another very positive step forward for the group as it continues to expand its customer base and global footprint. In our view, it shouldn’t be too long before the shares break out of their current trading range and begin a fresh leg higher."
dilip40: co growing at 30%pa with high recurring income at 3.2p eps and a pe of 20 would give a share price of 64p comments?
breaktwister: Share price hasn't moved on this in nearly 2 months. 2 buys at over £100k each this afternoon.
rivaldo: Very good news yesterday - could lead to a lot more work. I can see the share price moving back up to 45p for starters now.
glasshalfull: Few interesting snippets in this article... MIDLANDS BUSINESS NEWS Ideagen bullish about growth prospects By Edward Devlin, Midlands Correspondent 20 January 2014 Business Derbyshire software supplier Ideagen's management team have told Insider they are confident about the company's outlook for its second half with revenue set to nudge closer to £10m. The acquisitive company is also on the look out for further deals with ambitions to takeover one earnings enhancing business a year, chief executive David Hornsby and finance director Graeme Spenceley added. Based in the Lime Tree Business Park in Matlock, Ideagen was admitted to AIM in July 2012. Last week (14 January 2014), the business posted a 43 per cent rise in revenue to £3.7m in its first half. It was the ninth consecutive period of growth for the group. Pre-tax profit for the six months ended 31 October 2013 was also up from £230,403 to £515,105. Adjusted EBITDA increased by 59 per cent to £1.2m. The strong organic underlying growth of 16 per cent was driven by a significant increase in revenue generated within the UK healthcare sector, Ideagen chief executive David Hornsby said at the time. Full-year forecasts for adjusted EBITDA are £2.8m, slightly weighted towards the second half, with revenue set to grow by 42 per cent to £9m, which will include contribution from the latest acquisition, software developer MSS Management Systems Services. Finance director Graeme Spenceley told Insider: "There is quite a lot in the pipeline and in procurement in terms of health service contracts already for the second half so we are confident where we think we'll be at the end of the full year." Hornsby added that Ideagen was aiming to double the share price every three years as a baseline goal, which would put shares at about 60p each in 2017 and £1.20 by 2020. He said if the company could continue to boost its earnings by about 20 per cent a year, grow organically by 10 per cent and complete one earnings enhancing acquisition then the ambition was attainable. "We are certainly looking at further acquisitions in the next six to 12 months, but it will probably be in the next financial year," Hornsby said. "We are always open to deals and if something came very quickly out of nowhere and it was very attractive then we would have a look at it; particularly if it came out of cashflow." The business has completed five transactions since 2011, including MSS in 2013 and Plumtree Group in 2012. It raised £6m at the time of the Plumtree deal from a placing to fund future acquisitions. Hornsby and Spenceley both talked up the boost the business has received since its listing to AIM in 2012. "The AIM listing has been very good," Hornsby said. "It has given us credibility and it has given us access to the capital markets. We used to be on Plus markets and we raised money on the promise from certain institutions that we would move to AIM. We raised £6m 12 months ago [at the time of the Plumtree deal], which we wouldn't have been able to do if we weren't on AIM. "I think AIM has been a very good environment for us to grow." Spenceley echoed the sentiments and the pair agreed the process wasn't for the faint hearted. However, Spenceley added that any company thinking of floating on AIM needs to use the market to their advantage. "There is no point in going to AIM and then just sitting there and doing nothing," he said. "The whole point is the access to the capital market really. You need to have a requirement for capital, otherwise it is pointless." --- Regards, GHF
yump: I have nothing to be bitter about. Sold several lots of CBUY on the way up, missed the last 10p. But that made the glass 4/5 full when I sold. The difference is, and its an important one, that CBUY had made very little progress as a business and yet the share price shot up. I was just contrasting the two businesses. For me, target selling prices move up with business progress, not with a multiple of my purchase price. Except when a share price flies way, way ahead of any credible valuation. Then I just cash in my good luck. Good luck with your investments, whatever your strategy. (btw I think it was the % of savings business model change that sent CBUY up, combined with the CEO's £50mln revenue comment in the AGM)
masurenguy: Transcript Generating ideas is the way ahead When it comes to smaller companies delivering impressive growth, it's seldom driven purely organically. Moreover, it is often acquisition-led, with the organic element evolving after the integration process of bolt-on purchases have been bedded down. While there are a number of stocks out there with prospects, few tick the right boxes for me, although I confess to feeling that Matlock-based Ideagen does warrant a closer look. At the current 21p per share, and with a market cap of £25m, this provider of software management solutions addressing the vast area of industry compliance has been making some decent headway over the last few years, and appears well placed to continue on a growth path. A quick glance at Ideagen's revenues reveals sales gathering momentum having moved up from just a few hundred thousand in 2009 to the most recent £6.5m delivered for the year ended April of this year. And it is worth noting that those last numbers represented a significant 63% increase on the previous year. Although there have been acquisitions here which have contributed to the sales surge, there is also some decent organic growth feeding through along with the welcome addition of solid recurring revenues. Perhaps more attractive from a potential investment perspective is the ability of the company to generate cash and thus far, the boards reliability to deliver on anticipated numbers. With the company focused on providing its services to highly regulated industries such as health care, construction, aerospace and defence, along with utilities, there should be plenty of opportunities for the company ahead. In fact, within healthcare, whereby it already serves more than 350 hospitals across both the UK and the US, it looks well placed to further capitalise on progress already made. Its solutions and offerings which take in training, installation and maintenance are perhaps ideally suited for markets such as health-providing cost savings, efficiency and the raising of standards. Ideagen can also boast a specialist division purely dedicated to the NHS market with solutions delivered for the likes of patient medical record management, as one example. And that area could well be boosted by the company's most recent acquisition in the form of MSS, which follows on from the purchase of Proquis in 2011 and Plumtree which was acquired in 2012. This latest addition is focused on information management solutions delivering its Patient First product to the Accident and Emergency departments of at least 10 Acute trusts within England. Given the ongoing concerns in relation to A&E departments coming under increased pressure, any system that enhances the service or helps manage vast numbers flowing through the system should be likely to benefit further ahead. Thus far, the enlarged Ideagen is performing well and successfully raised £6m in an over-subscribed placing last year which contributed to the purchase of Plumtree, a complementary business also UK-based which provides strong synergies and further opportunities. One minor hiccup came in the form of the early termination of a contract in the US when the Dept of Veteran Affairs found its budget coming under pressure. Although an inconvenience, it didn't really impact on the share price or it would seem the longer term business potential. Since then, the company has delivered its preliminary results which were released back in July and things appear well on track. Solid cash generation along with a decent line of recurring revenue saw pre-tax profits after amortisation and intangibles related to the acquisitions come in at £1.8m. Cash on the balance sheet is also solid standing at £6.3m, which gives the company more scope to add another complementary business should it choose to do so. Additionally, a further contract was also announced with the Dartford and Gravesham NHS Trust signing up for a document management solution. Broker FinnCap is forecasting adjusted pre-tax profits of £2.6m for next year which would give EPS of 1.6p putting the shares on a forward PER of just over 12. While that may not appear overly cheap, it is nevertheless at a discount to peers and needs to be looked at in the context of how quickly the business may grow over the next few years and beyond. Of course, some may want to see more evidence of the board's ability to maximise the benefits from the acquisitions and that is reasonable. However, if it does continue in the recent vein, then the shares in turn could appreciate quite quickly and achieve the current broker target price of 27p. Major holders include Investec, Octopus, ISIS and Amati Global.
battlebus2: I think the big news here is the excellent management and their ability to continue this company on a growth path by winning new contracts etc and the respect they have for shareholders in adding value steadily increasing the share price. The market has recognised this so downside will be limited imv but dyor.
chizgreen68: I agree yump. I have been lazy and not worked out the current pe, but imagine its a bit ahead of actual profits. That being said, I like the quality of the earnings here and the market is clearly there to achieve the share price (doubling every 3 years) that the CEO aspires to. I expect to hold for another 5 years, at a minimum, and worry less about this share than most others I hold

Ideagen Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
O 43,102 46.05 13 Oct 2015 15:18:25 GBX

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 151013 16:43